// App-Quantinova.ai

: Investigating effects of nintedanib on biomarkers of ECM turnover in patients with IPF: the INMARK study

Researchers

Presenter

  • Toby Maher

Principal Investigators

  • Susanne Stowasser

  • Yasuhiko Nishioka

  • Eric S White

  • Vincent Cottin

  • Imre Noth

  • Moises Selman

  • Daniel Wachtlin

  • Claudia Diefenbach

  • R Gisli Jenkins

Medical Centers

  • National Institute for Health Research Respiratory Biomedical Research Unit, Royal Brompton and Harefield NHS Foundation Trust, and National Heart and Lung Institute, Imperial College, London, UK and Fibrosis Research Group, National Heart and Lung Institute, Imperial College, London, United Kingdom.

  • Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany,

  • Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan

  • University of Michigan, Division of Pulmonary & Critical Care Medicine, Ann Arbor, MI, United States,

  • Louis Pradel Hospital, Claude Bernard University Lyon 1, Lyon, France,

  • Pulmonary and Critical Care Medicine, University of Chicago, Chicago, Illinois, United States of America

  • Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico

  • Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach, Germany

  • University of Nottingham, Nottingham, United Kingdom

Locations

  • United Kingdom

  • Germany

  • Japan

  • United States

  • France

  • Mexico

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Peritoneal colorectal carcinomatosis

Biomarkers

  • Matrix metalloproteinase 1

Drug/Treatment

  • Nintedanib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Open Label

Phase

  • NA

Study Id's

  • NCT02788474

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved